Ramy A. Mahmoud Sells 111,426 Shares of OptiNose, Inc. (NASDAQ:OPTN) Stock

OptiNose, Inc. (NASDAQ:OPTN) CEO Ramy A. Mahmoud sold 111,426 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total value of $127,025.64. Following the completion of the sale, the chief executive officer now owns 1,206,978 shares in the company, valued at $1,375,954.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

OptiNose Stock Performance

OPTN stock traded down $0.02 during midday trading on Thursday, reaching $1.08. 669,865 shares of the company traded hands, compared to its average volume of 882,190. OptiNose, Inc. has a 52-week low of $0.80 and a 52-week high of $2.10. The business has a 50 day moving average of $1.13 and a 200-day moving average of $1.28. The firm has a market capitalization of $122.08 million, a price-to-earnings ratio of -4.04 and a beta of -0.12.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The business had revenue of $14.88 million during the quarter, compared to analyst estimates of $13.95 million. Research analysts anticipate that OptiNose, Inc. will post -0.26 earnings per share for the current year.

Institutional Investors Weigh In On OptiNose

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. bought a new position in shares of OptiNose during the fourth quarter valued at approximately $47,000. MVM Partners LLC bought a new position in OptiNose in the fourth quarter worth approximately $18,768,000. Kingdon Capital Management L.L.C. grew its stake in OptiNose by 5.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,899,237 shares of the company’s stock worth $5,030,000 after purchasing an additional 200,000 shares in the last quarter. Palumbo Wealth Management LLC bought a new position in OptiNose in the fourth quarter worth approximately $33,000. Finally, HighMark Wealth Management LLC bought a new position in OptiNose in the first quarter worth approximately $36,000. 85.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OPTN has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of OptiNose in a research report on Wednesday, May 15th. Lake Street Capital decreased their target price on OptiNose from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Wednesday, May 15th.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.